Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Launch Diagnostics looks like a very good buy. A solid piece of business done by the team. It’s a proper Company with recurring revenues and well aligned for us. Very well handled funding. I think the board have been really well advised.
The underlying tone, and the planning and direction feel so right for the next couple of months and on from there.
So exciting.
I think 3 plus 10% inflation on the ex China over last 12 months = £220
A watched pot never boils!
To fair, the patients in the trial will rightly be a lot more anxious about the difference AVA6k might make for them than any of us and then what a breakthrough for millions of others, in time, who haven’t even been diagnosed.
Good luck all, great things just around the corner.
Common sense says they wouldn’t be plying a patient with a totally inert and useless treatment that after 400 odd days had shown no signs of working. I can’t conceivably imagine that previous levels didn’t work and they’ve just said let’s keep going until it does.
Whichever way one looks at it, the longevity of the trial tells us what we want to know and hopefully has made a big difference to patients.
.
We shall not be moved. :)
Thanks energy for a very useful post. I’ve followed up. Will post up if I get any response.
I think most of us are still here for a good reason. It is pretty compelling, whatever doubts may linger. The trial is clearly going the right way or would have been pulled by now. It’s out of Avacta’s hands for now, it can’t go on for ever and we’ll soon know. We wait for the white smoke and the subsequent journey.
RIP our wonderful Queen. A consistent and proper example to so many. Will miss you hugely.
Smart work Mart, thank you
Likewise, not expecting data for a few weeks. Of course the quality of reporting of the study results must be quite a task in order to deliver maximum credibility, with a flawless representation to the audience.
Having no prior experience of this, I’d be interested to get an insight on what detail/format to expect from the PK data results, when they’re ready.
We know the crux of the outcome we’re looking for Re FAP and toxicity, just interested to know if it’s likely to be delivered as a simple debrief on those 2 points or is the reporting task much deeper, nuanced and complex.
I’m pretty convinced we’ll be receiving an outstanding outcome, just don’t know how we’ll be told about it and when we know it’s either cut and dried full speed to next stage or could we have variations.
Well done to everyone, thoroughly deserved. Top talented and focused team.
Many congrats to all
Nice RNS. It would be very odd indeed to be making the steps they’ve introduced and the hires, whilst sitting on a poorly progressing trial. It would make no sense.
Could be quite a time ahead of us over the coming weeks. Trying not to think about it too much.
Big thanks to Energyshares for the ‘Why’ post, so true.
Seems to me AVA6000 success would inevitably put TMAC straight in with a top shot of coming off. I can’t imagine the value of an even better follow up solution following the success of a breakthrough Chemo delivery system. The whole business would be simply priceless and possibly not far away from realising that over the next few months.
Good job. High quality, solid and honest representation of progress. No over-promising. Very happy with this and very re-assured.
If you are reading, please confirm that we are no longer paying for your scaled up diagnostics team and the related hires that were made in terms of sales, marketing and distribution. I assume this has already been taken care of? Appreciate it didn’t come off as you’d hoped but keen to know that the overhead has been culled swiftly and according to the new circumstances. Be good to know that’s of course already in hand.
A fair assessment and I agree we could reach a valuation of that height or more and of course other posters have applauded our leader on his great ability as a scientist, which I don’t deny but I do so feel that he and his complicits have, on the way, danced us a tune.
I would not have taken part, nor would anyone else, if we’d been briefed properly on the risk and reward, which we were not.
Icecool, well said. I’m not keen on making SP predictions for the main reason that I’m generally hugely wrong, I am though very keen on the Company providing us with a true and consistent narrative upon which we can base our financial decisions, which they have not done.
I’d expect our CEO to lead in every aspect of our management team: product and development, sales, finance, PR and comms etc. Our CEO has been poor on most of these, maybe all. He hasn’t done any of this well.
Who the hell is doing their job on the board and holding him to account, because it’s not been a job well done in any conceivable way, either by him
or those who are supposed to overview him on our behalf. It’s been an embarrassment. The non execs have a duty, are trained, certified and will be held to account. We know who they are and what they are supposed to have done. They haven’t done the job that we are paying them for.
With regards Ava, I had some confidence, until our CEO bottled out in that last ridiculous video and asked his colleague to lead the presentation. Fiona M did a good job because he told her to but she provided a slightly different narrative to the one we had been previously given by AL. If I’d heard Fiona’s story from the onset, I’d have taken a different view and would have taken a different investment decision. I’ve made my decisions, at every stage, based on the information the Company has provided.
It’s not good enough and not enough for us as investors to rely on acrimonious posts to solve the problem which needs urgent intervention.
I think AS has been provided half truths and not been straight with the market. Now that he has so nonchalantly dismissed our LFDs, what he really should do is to tell us how he plans to cut a large payroll cost out of our diagnostics, or show us a viable set of achievable goals and targets over the next 6 months, or he should leave along with the diagnostic team.
Up to now he’s given us a load of waffle and vague reasons for why things have not happened.
I don’t think AS should be leading this business through therapeutics. He has shot all of his credibility and we need a star CEO who can take charge and realise the huge potential we still have.
Thanks Sorcerer, very interesting.